Madrigal Pharmaceuticals (MDGL) shares advanced nearly 21% in recent Wednesday trading after the company released results for Q4 and new data on its Rezdiffra drug.
The company reported a Q4 net loss of $2.71 per diluted share on revenue of $103.3 million, topping market expectations.
The company also said patients with metabolic dysfunction-associated steatohepatitis treated with its Rezdiffra drug showed "marked reductions" in liver stiffness.
Price: 373.33, Change: +63.84, Percent Change: +20.63
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.